GlassScriptPhysician profile
David Russell Smith
NPI 1679520050
$487.58
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $488.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $44.64 | 2022 | |
| Sk Life Science, INC. | $40.13 | 2022 | |
| Spr Therapeutics, INC | $40.00 | 2022 | |
| Neurocrine Biosciences, INC. | $39.06 | 2022 | |
| Avanir Pharmaceuticals, INC. | $39.00 | 2022 | |
| Merck Sharp & Dohme LLC | $36.00 | 2022 | |
| Eisai INC. | $32.93 | 2022 | |
| Lilly USA, LLC | $30.53 | 2022 | |
| Ucb, INC. | $26.67 | 2022 | |
| Alexion Pharmaceuticals, INC. | $23.36 | 2022 | |
| Medtronic, INC. | $21.09 | 2022 | |
| Amgen INC. | $19.72 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $18.73 | 2022 | |
| Amneal Pharmaceuticals LLC | $17.23 | 2022 | |
| Banner Life Sciences, LLC | $16.44 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $15.40 | 2022 | |
| Celgene Corporation | $13.50 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.15 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.